[go: up one dir, main page]

GB2278780B - Macrolide formulations - Google Patents

Macrolide formulations

Info

Publication number
GB2278780B
GB2278780B GB9410252A GB9410252A GB2278780B GB 2278780 B GB2278780 B GB 2278780B GB 9410252 A GB9410252 A GB 9410252A GB 9410252 A GB9410252 A GB 9410252A GB 2278780 B GB2278780 B GB 2278780B
Authority
GB
United Kingdom
Prior art keywords
macrolide
formulations
macrolide formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9410252A
Other versions
GB2278780A (en
GB9410252D0 (en
Inventor
Gerd Fricker
Barbara Haeberlin
Armin Meinzer
Jacky Vonderscher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Sandoz AG
Original Assignee
Ciba Geigy AG
Novartis AG
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939310974A external-priority patent/GB9310974D0/en
Priority claimed from GB939320463A external-priority patent/GB9320463D0/en
Application filed by Ciba Geigy AG, Novartis AG, Sandoz AG filed Critical Ciba Geigy AG
Priority to GB9410252A priority Critical patent/GB2278780B/en
Priority to GB9722958A priority patent/GB2315216B/en
Publication of GB9410252D0 publication Critical patent/GB9410252D0/en
Publication of GB2278780A publication Critical patent/GB2278780A/en
Application granted granted Critical
Publication of GB2278780B publication Critical patent/GB2278780B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB9410252A 1993-05-27 1994-05-23 Macrolide formulations Expired - Fee Related GB2278780B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB9410252A GB2278780B (en) 1993-05-27 1994-05-23 Macrolide formulations
GB9722958A GB2315216B (en) 1993-10-05 1994-05-23 Microemulsion preconcentrates comprising FK506 or 33-epi-chloro-33-desoxy-ascomycin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939310974A GB9310974D0 (en) 1993-05-27 1993-05-27 Organic compounds
GB939320463A GB9320463D0 (en) 1993-10-05 1993-10-05 Organic compounds
GB9410252A GB2278780B (en) 1993-05-27 1994-05-23 Macrolide formulations

Publications (3)

Publication Number Publication Date
GB9410252D0 GB9410252D0 (en) 1994-07-13
GB2278780A GB2278780A (en) 1994-12-14
GB2278780B true GB2278780B (en) 1998-10-14

Family

ID=27266701

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9410252A Expired - Fee Related GB2278780B (en) 1993-05-27 1994-05-23 Macrolide formulations

Country Status (1)

Country Link
GB (1) GB2278780B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026290B1 (en) 1998-12-30 2006-04-11 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosprin
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1009856A5 (en) 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US6239124B1 (en) 1996-07-30 2001-05-29 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
DE19635553A1 (en) * 1996-09-02 1998-03-05 Henkel Kgaa Emulsifier mixtures
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
PL342742A1 (en) * 1998-03-06 2001-07-02 Novartis Ag Emulsion-type pre-concentrates containing cyclosporin or macrolyde
ID25908A (en) * 1998-03-06 2000-11-09 Novartis Ag EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES
GB2380674B (en) * 1998-03-06 2003-05-28 Novartis Ag Emulsion preconcentrates containing cyclosporin or a macrolide
TW537894B (en) * 1998-05-26 2003-06-21 Novartis Ag A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
GB9912476D0 (en) 1999-05-28 1999-07-28 Novartis Ag Organic compounds
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
BRPI0607606B1 (en) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. LIQUID FORMULATION
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
JP5506378B2 (en) 2006-03-23 2014-05-28 参天製薬株式会社 Formulations and methods for diseases or conditions associated with vascular permeability

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB907430A (en) * 1960-02-04 1962-10-03 Abbott Lab A method for the preparation of chemically stable liquid suspensions of erythromycinand the suspensions so prepared
GB1322306A (en) * 1971-04-15 1973-07-04 Meiji Seika Co Stabilized antibiotic preparation and manufacturing process therefor
EP0041795A2 (en) * 1980-06-02 1981-12-16 Ayerst, Mckenna And Harrison Inc. Injectable composition of rapamycin
JPS61291520A (en) * 1985-06-19 1986-12-22 Daigo Eiyou Kagaku Kk Fat emulsion of erythromycin
EP0302370A1 (en) * 1987-08-07 1989-02-08 Abbott Laboratories Erythromycin formulations for oral administration
GB2222770A (en) * 1988-09-16 1990-03-21 Sandoz Ltd Cyclosporin emulsion compositions
EP0361928A2 (en) * 1988-09-29 1990-04-04 Shiseido Company Limited Emulsified composition
WO1990014094A1 (en) * 1989-05-26 1990-11-29 Abbott Laboratories Injectable clarithromycin composition
EP0483842A1 (en) * 1990-11-02 1992-05-06 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical compositions containing tricyclic compounds
GB2257359A (en) * 1991-06-27 1993-01-13 Sandoz Ltd Cyclosporin compositions for oral administration
WO1993020833A1 (en) * 1992-04-22 1993-10-28 Sandoz Ltd. Pharmaceutical composition containing cyclosporin derivative

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB907430A (en) * 1960-02-04 1962-10-03 Abbott Lab A method for the preparation of chemically stable liquid suspensions of erythromycinand the suspensions so prepared
GB1322306A (en) * 1971-04-15 1973-07-04 Meiji Seika Co Stabilized antibiotic preparation and manufacturing process therefor
EP0041795A2 (en) * 1980-06-02 1981-12-16 Ayerst, Mckenna And Harrison Inc. Injectable composition of rapamycin
JPS61291520A (en) * 1985-06-19 1986-12-22 Daigo Eiyou Kagaku Kk Fat emulsion of erythromycin
EP0302370A1 (en) * 1987-08-07 1989-02-08 Abbott Laboratories Erythromycin formulations for oral administration
GB2222770A (en) * 1988-09-16 1990-03-21 Sandoz Ltd Cyclosporin emulsion compositions
EP0361928A2 (en) * 1988-09-29 1990-04-04 Shiseido Company Limited Emulsified composition
WO1990014094A1 (en) * 1989-05-26 1990-11-29 Abbott Laboratories Injectable clarithromycin composition
EP0483842A1 (en) * 1990-11-02 1992-05-06 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical compositions containing tricyclic compounds
GB2257359A (en) * 1991-06-27 1993-01-13 Sandoz Ltd Cyclosporin compositions for oral administration
WO1993020833A1 (en) * 1992-04-22 1993-10-28 Sandoz Ltd. Pharmaceutical composition containing cyclosporin derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chem.Abs.106:162589 & JP 61291520 A *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026290B1 (en) 1998-12-30 2006-04-11 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosprin
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin

Also Published As

Publication number Publication date
GB2278780A (en) 1994-12-14
GB9410252D0 (en) 1994-07-13

Similar Documents

Publication Publication Date Title
EP0721328A4 (en) Camptothecin formulations
EP0634459A3 (en) Formulations.
IL111004A0 (en) Oral rapamycin formulations
IL111978A (en) Dry-compressed paroxetine formulations
ZA942814B (en) Agricultural formulations
ZA946195B (en) Anthelmintic formulations
GB2278780B (en) Macrolide formulations
GB9214390D0 (en) Formulations
GB9303832D0 (en) Speculum
GB9311030D0 (en) Pharmaceutical formulations
GB9323399D0 (en) Pharmaceutical formulations
GB9609203D0 (en) Formulations
GB2327611B (en) Macrolide compositions
HK1011278B (en) Macrolide formulations
GB9308622D0 (en) Formulations
GB9306144D0 (en) Formulations
GB9205739D0 (en) Formulations
GB9213271D0 (en) Formulations
GB9205738D0 (en) Formulations
GB9202474D0 (en) Formulations
GB9224539D0 (en) Formulations
GB9608869D0 (en) Antibiotic formulations
GB9508144D0 (en) Formulations
GB9509941D0 (en) Formulations
GB9510349D0 (en) Formulations

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20120523